B
Bull
Bull · 25%LUCD
$2.49
Scenario price
$0.411
+0.104 (+25.42%)At close
Loading chart…
- High
- 0.453
- Open
- 0.434
- VWAP
- 0.42
- Volume
- 109.88M
- Mkt Cap
- 45.55M
- Low
- 0.388
- Amount
- 45.84M
- EV/EBITDA, TTM
- -0.38
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc.
AI analysis of Lucid Diagnostics Inc (LUCD)
SellLucid Diagnostics Inc is not a good buy right now due to its extremely low RSI of 14.018, indicating oversold conditions, and a staggering year-to-date change of -57.32%. The stock is currently trading at $0.48, significantly below its analyst price target of $3, but the risks are substantial with a negative gross margin of -5.16% in Q2 2026 and ongoing losses.
Valuation Metrics
The current forward P/E ratio for Lucid Diagnostics Inc (LUCD) is 0.00, compared to its 5-year average forward P/E of -2.03.
Alphio AI Price Scenarios for LUCD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LUCD
Events Timeline
News
7.510-23NewsfilterKraig Biocraft Advances Commercialization of Spider Silk Technology
8.510-22PRnewswireLucid Begins Medicare Claims for EsoGuard Test, Secures $15M Funding
4.510-01FoolStellantis Unveils $70 Billion Global Turnaround Plan
9.508-14PRnewswirePAVmed Provides Business Update and Q2 Financial Results
9.508-13PRnewswireLucid Diagnostics Reports Q2 2026 Financial Results and Business Update
LUCD FAQ — answered by Alphio AI
Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company's products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The Company is a subsidiary of PAVmed Inc. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Lucid Diagnostics Inc is not a good buy right now due to its extremely low RSI of 14.018, indicating oversold conditions, and a staggering year-to-date change of -57.32%. The stock is currently trading at $0.48, significantly below its analyst price target of $3, but the risks are substantial with a negative gross margin of -5.16% in Q2 2026 and ongoing losses.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.